Metastatic Hormone Receptor-Positive Breast Carcinoma
specificHormone receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.
22
Centers
5
Active Trials
—
Cancer Funding
Top Centers for Metastatic Hormone Receptor-Positive Breast Carcinoma(22)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Siteman Cancer CenterSt. Louis, MO NCI Comprehensive High-Volume Research Center | 73.8 |
| 2 | Fred Hutch Cancer CenterSeattle, WA NCI Comprehensive Active Research Program | 69.7 |
| 3 | NCI Comprehensive Active Research Program | 69.7 |
| 4 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive Active Research Program | 69.7 |
| 5 | UPMC Hillman Cancer CenterPittsburgh, PA NCI Comprehensive | 48.2 |
| 6 | Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive | 48.2 |
| 7 | NCI Comprehensive | 48.2 |
| 8 | NCI Comprehensive | 48.2 |
| 9 | Masonic Cancer CenterMinneapolis, MN NCI Comprehensive | 48.2 |
| 10 | NCI Comprehensive | 48.2 |
| 11 | NCI Comprehensive | 48.2 |
| 12 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive | 48.2 |
| 13 | NCI Clinical | 48.2 |
| 14 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive | 48.2 |
| 15 | VCU Massey Comprehensive Cancer CenterRichmond, VA NCI Comprehensive | 48.2 |
| 16 | University of Illinois Cancer CenterChicago, IL | 48.2 |
| 17 | Boston University Cancer CenterBoston, MA | 48.2 |
| 18 | Cancer Center at IllinoisUrbana, IL | 48.2 |
| 19 | Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL | 48.2 |
| 20 | Mayo Clinic Comprehensive Cancer Center, ArizonaScottsdale, AZ | 48.2 |
| 21 | 48.2 | |
| 22 | University of Texas Medical Branch Cancer CenterGalveston, TX | 48.2 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →